Inflammatory Bowel Disease Is an Independent Risk Factor for Metabolic Dysfunction-Associated Steatotic Liver Disease in Lean Individuals [0.03%]
炎症性肠病是消瘦个体中代谢功能紊乱相关肝脂肪变性的独立危险因素
Samuel J Martínez-Domínguez,Sandra García-Mateo,Carla J Gargallo-Puyuelo et al.
Samuel J Martínez-Domínguez et al.
Background: Despite classical association between metabolic dysfunction-associated steatotic liver disease (MASLD) and obesity, there is increasing evidence on the development of MASLD in lean individuals. The aim of the ...
Prevalence and Treatment Patterns of Inflammatory Bowel Disease in the All of Us Research Program [0.03%]
美国国家卫生研究院全民医学研究项目中炎症性肠病的流行病学和治疗特点分析
Michaela S Tracy,Prasanna K Challa,Emily W Lopes et al.
Michaela S Tracy et al.
Children and Young Adults With Inflammatory Bowel Disease Have an Increased Incidence and Risk of Developing Mental Health Conditions: A UK Population-Based Cohort Study [0.03%]
炎症性肠病患儿和青年的发病率和精神健康状况患病风险增加：基于英国的人群队列研究
Rachel Cooney,Daniel Tang,Kevin Barrett et al.
Rachel Cooney et al.
Background: The burden of mental health conditions in children and young adults with inflammatory bowel disease remains unclear. We assessed this using a primary care database in the United Kingdom. ...
Inflammatory Bowel Diseases-related Disability: Risk Factors, Outcomes, and Interventions [0.03%]
炎症性肠病相关的残疾：风险因素、结局和干预措施
Chung Sang Tse,Melissa G Hunt,Lily A Brown et al.
Chung Sang Tse et al.
The diagnosis of inflammatory bowel disease (IBD) is a life-changing moment for most adults. Biomedical advances over the past 2 decades have resulted in unprecedented growth of therapeutic options for IBD. However, due to the incurable nat...
The Communicating Needs and Features of IBD Experiences (CONFIDE) Study: US and European Patient and Health Care Professional Perceptions of the Experience and Impact of Symptoms of Moderate-to-Severe Ulcerative Colitis [0.03%]
关于炎症性肠病体验的沟通需求和特点（CONFIDE）研究：美国和欧洲患者及医务工作者对中至重度溃疡性结肠炎症状体验与影响的认知
Simon Travis,Alison Potts Bleakman,Marla C Dubinsky et al.
Simon Travis et al.
Background: The Communicating Needs and Features of IBD Experiences (CONFIDE) study aimed to evaluate the experience and impact of ulcerative colitis (UC) symptoms on patients' lives and elucidate gaps in communication be...
A Treat-to-Target Strategy Guided by Pan-Enteric Evaluation in Children With Crohn's Disease Improves Outcomes at 2 Years [0.03%]
基于全小肠评估的克罗恩病患儿治疗目标策略改善了两年后的预后
Giulia D&#x;Arcangelo,Giusy Russo,Marina Aloi et al.
Giulia D&#x;Arcangelo et al.
Background and aims: It is uncertain whether a treat-to-target approach could be an effective strategy for improving outcomes in children with Crohn's disease (CD). Previously, we reported mucosal healing (MH) and deep re...
Thea Vestergaard,Jens Kelsen,Mette Julsgaard
Thea Vestergaard
Implication of Inflammatory Bowel Disease Diagnosed Before the Age of 18 for Achieving an Upper Secondary Education: A Nationwide Population-Based Cohort Study [0.03%]
一项基于全国人口的队列研究：在18岁之前诊断炎症性肠病对获得高级中学教育的影响
Julie Rasmussen,Bente Mertz Nørgård,Rasmus Gaardskær Nielsen et al.
Julie Rasmussen et al.
Background: Educational achievement may be adversely affected by chronic conditions in childhood and adolescence. This study aimed to examine the effect of being diagnosed with IBD on achievement of an upper secondary edu...
Safety, Effectiveness, and Treatment Persistence of Subcutaneous Vedolizumab in IBD: A Multicenter Study From the United Kingdom [0.03%]
英国一项多中心研究：维多珠单抗治疗炎症性肠病的安全性、有效性和持续治疗率
Samuel Hsiang Lim,Beatriz Gros,Esha Sharma et al.
Samuel Hsiang Lim et al.
Background and aims: Despite intravenous (IV) vedolizumab being established for treatment of inflammatory bowel disease (IBD), the novel subcutaneous (SC) route of administration may provide numerous incentives to switch....
Predictive Factors for Efficacy of Oral Tacrolimus Induction Therapy in Moderate to Severe Ulcerative Colitis Patients: Large Multicenter Retrospective Cohort Study [0.03%]
口服他克莫司诱导治疗中重度溃疡性结肠炎疗效的影响因素：大样本多中心回顾性队列研究
Naoki Oshima,Sakiko Hiraoka,Ryohei Hayashi et al.
Naoki Oshima et al.
Background: Tacrolimus (TAC), a calcineurin inhibitor, is used for remission induction therapy in patients with moderate to severe ulcerative colitis (UC), with short-term efficacy and related predictive factors shown in ...